She advised on the study design and commented on drafts of the paper. BD was a grant holder on the study and was involved in the initial design of the study. All Authors state that they had complete access to the study data that support the publication. “
“Objectives Few studies have explored pharmacists’ perceptions of their potential http://www.selleckchem.com/products/r428.html role in asthma management. This study aimed to investigate community pharmacists’
perceptions of their role in the provision of asthma care, to compare the perceptions of metropolitan and regional pharmacists with regards to their role, to identify barriers to the provision of asthma management services and to explore their level of inter-professional contact. Methods A 29-item questionnaire was mailed to a convenience sample of community pharmacists. Items included pharmacists’ perceptions of their role in asthma management, barriers to pharmacy asthma services and inter-professional Selleckchem BMN673 contact.
The setting was community pharmacies in metropolitan and rural New South Wales, Australia. Key findings Seventy-five pharmacists (63% male, 69% in metropolitan pharmacies) returned completed questionnaires (response rate 89%). Pharmacists perceived their role in asthma management along three major dimensions: ‘patient self-management’, ‘medication use’ and ‘asthma control’. Regional pharmacists described a broader role than metropolitan pharmacists. Most participants perceived time and patient-related factors to be the main barriers to optimal asthma care with pharmacist’s lack of confidence and skills in various aspects of asthma care less important barriers. Almost 70% indicated that they would like more inter-professional contact regarding the care of patients with asthma. Conclusions Community
pharmacists perceived a three-dimensional role in asthma care with regional pharmacists more likely to embrace a broader role in asthma management compared to metropolitan pharmacists. Pharmacists identified time and patient-related factors as the major barriers to the provision of asthma services. Future research should explore barriers and facilitators to expansion of the pharmacist’s role in asthma management in a holistic way. Healthcare is an evolving arena in which increased levels of consumer Ibrutinib cell line involvement and expectation, government, changing patient demography and technology are the main drivers of change. In chronic disease states there has been a shift towards greater involvement and collaboration of allied health professionals in the community setting for more comprehensive disease management, improved patient outcomes and satisfaction as well as cost savings. Asthma is a typical example of a chronic disease state in which community pharmacists have been actively engaging in a range of disease and patient-centred management services for adults, resulting in improved asthma outcomes and reductions in healthcare costs.